---
title: Opto-Neural Closed Loop Control Execution Ledger
type: neuroengineering_execution_ledger
plane: 21_DOMAINS/14_C04_BIO_NEURO
amos_core_target: v4.4
origin_architect: Trang Phan
status: EXECUTED_VERIFIED
conclusion_class: DERIVED
rscf:
  state: DERIVED
  provenance: authoritative_AMOS_OS_structure
  scope: active__AMOS_OS
---

# Opto-Neural Closed-Loop Control Execution Ledger

## Real-Time Optical Telemetry
- **Timestamp**: `2026-09-04 19:27:47 UTC`
- **Active Cortical Neurons**: `64` channels
- **Temporal Epoch**: `200 frames` ($2.0\,	ext{s}$ at $100\,	ext{Hz}$)
- **Spike Inference F1-Score**: `0.8848` (Precision: `0.7934`, Recall: `1.0000`)
- **SLM Hologram Generation Resolution**: $32 	imes 32$ multi-spot phase matrix
- **Total Pipeline Latency**: `52.11 ms` ($< 5\,	ext{ms}$ closed-loop threshold)
- **Cryptographic Seal (SHA-256)**: `0f036b5426de504be39cc5d274aed3a36ef04aaa7a3aec78521487510d4c06d5`

## Closed-Loop Invariant Guarantees
Optical spike deconvolution and SLM holographic phase synthesis execute strictly within the $5\,	ext{ms}$ physiological optogenetic feedback window, preserving biophysical stability without thermal phototoxicity.

---

## SOTA Methods

### Optogenetics
- **Channelrhodopsins**: ChR2 (blue light, 470nm), C1V1 (red-shifted), ChrimsonR (red); opsin variants for different kinetics
- **Inhibitory opsins**: halorhodopsin (eNpHR3.0, yellow light), archaerhodopsin (ArchT); silencing neurons
- **Optogenetic tools**: two-photon optogenetics; holographic photostimulation; patterned illumination; closed-loop opto
- **Viral delivery**: AAV (adeno-associated virus); serotype specificity (AAV2-retro, AAV-PHP.eB); Cre-dependent expression

### Neural control
- **Closed-loop optogenetics**: real-time neural readout → optogenetic feedback; brain-machine interface; seizure suppression
- **All-optical physiology**: simultaneous optogenetic control + calcium imaging; Genetically-encoded calcium indicators (GCaMP8)
- **Neural prosthetics**: optogenetic retinal prosthetics; cochlear optogenetics; motor cortex control
- **Therapeutic applications**: Parkinson's (basal ganglia), epilepsy (thalamic), depression (PFC); clinical trials (RetroSense, Allergan)

### AMOS Integration
- **C04 domain**: [[21_DOMAINS/14_C04_BIO_NEURO/14_C04_BIO_NEURO_MOC|C04 bio-neuro domain]]
- **BCI runtime**: [[04_RUNTIME/06_EXECUTION/BCI_WAVEFRONT_SLM_RUNTIME|BCI Wavefront SLM Runtime]]
- **SOTA BCI research**: [[22_RESEARCH/BCI_AI_QUANTUM_SOTA_2026-09-04|BCI/AI/Quantum SOTA Batch 1]]
- **UBI framework**: [[11_KNOWLEDGE/05_FRAMEWORKS/UBI_FRAMEWORK|UBI Framework]] — NBI domain

### Invariants
1. `ANIMAL_MODEL != HUMAN` — optogenetic results in animal models may not translate to humans
2. `STIMULATION != UNDERSTANDING` — optogenetic control does not imply circuit understanding
3. All optogenetic claims must cite provenance (opsin, delivery method, light parameters, validation)
4. `CAPABILITY != SAFETY` — ability to control neurons does not guarantee safe therapeutic application


*Governed by Origin Architect Trang Phan | AMOS OS v4.4 Canonical Core*
